Repare Therapeutics (NASDAQ:RPTX) Given Market Perform Rating at Lifesci Capital

Repare Therapeutics (NASDAQ:RPTX)‘s stock had its “market perform” rating restated by research analysts at Lifesci Capital in a research report issued on Friday,Benzinga reports.

RPTX has been the topic of a number of other research reports. Stifel Nicolaus lowered their target price on shares of Repare Therapeutics from $9.00 to $4.00 and set a “buy” rating on the stock in a report on Friday. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Repare Therapeutics in a research note on Friday, November 8th.

Repare Therapeutics Stock Down 55.4 %

NASDAQ RPTX opened at $1.77 on Friday. The firm has a market cap of $75.24 million, a P/E ratio of -0.89 and a beta of 0.71. The company’s 50 day moving average is $3.30 and its 200-day moving average is $3.35. Repare Therapeutics has a 12-month low of $1.66 and a 12-month high of $8.49.

Hedge Funds Weigh In On Repare Therapeutics

Hedge funds have recently bought and sold shares of the company. Barclays PLC lifted its stake in Repare Therapeutics by 1,471.7% in the 3rd quarter. Barclays PLC now owns 8,330 shares of the company’s stock worth $29,000 after purchasing an additional 7,800 shares in the last quarter. Vontobel Holding Ltd. increased its holdings in shares of Repare Therapeutics by 20.0% in the third quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company’s stock worth $83,000 after purchasing an additional 4,000 shares during the period. XTX Topco Ltd bought a new position in shares of Repare Therapeutics in the second quarter worth $110,000. Exchange Traded Concepts LLC raised its position in shares of Repare Therapeutics by 21.2% in the third quarter. Exchange Traded Concepts LLC now owns 50,441 shares of the company’s stock worth $174,000 after buying an additional 8,809 shares in the last quarter. Finally, Stifel Financial Corp boosted its stake in Repare Therapeutics by 36.4% during the third quarter. Stifel Financial Corp now owns 51,700 shares of the company’s stock valued at $178,000 after buying an additional 13,800 shares during the period. Hedge funds and other institutional investors own 85.09% of the company’s stock.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.